Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection. Invivyd plans to seek accelerated approval for VYD2311 based ...
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content ...
Patients with early-onset, BRAF V600E–mutated metastatic colorectal cancer should receive combination therapy as soon as ...
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press. Insurance Business cited the AJMC study as evidence for its central argument: a larger PBM rebate ...
The FDA approved tucatinib (Tukysa; Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of ...
Sacral neuromodulation (SNM) is still considered the gold standard neuromodulation option for refractory overactive bladder ...
Risk assessment in mantle cell lymphoma (MCL) is evolving beyond traditional clinical scores, as genomic and dynamic ...
The FDA approved remibrutinib (Rhapsido; Novartis) today, October 7, 2026, as the first treatment for adults with symptomatic ...
Bilbrey’s Tennessee Oncology colleage Johnetta Blakely, MD, MS, MMHC, who is also chief medical officer for COA, has ...
Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.
Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.
Esperion launched a nationwide awareness campaign for bumetanide nasal spray (Enbumyst), a short-term intranasal loop ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results